Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2023

Open Access 05-10-2022 | Multiple Sclerosis | Original Article

Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP

Authors: Pedro Brugarolas, Moses Q. Wilks, Jacqueline Noel, Julia-Ann Kaiser, Danielle R. Vesper, Karla M. Ramos-Torres, Nicolas J. Guehl, Marina T. Macdonald-Soccorso, Yang Sun, Peter A. Rice, Daniel L. Yokell, Ruth Lim, Marc D. Normandin, Georges El Fakhri

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2023

Login to get access

Abstract

Purpose

[18F]3F4AP is a novel PET radiotracer that targets voltage-gated potassium (K+) channels and has shown promise for imaging demyelinated lesions in animal models of neurological diseases. This study aimed to evaluate the biodistribution, safety, and radiation dosimetry of [18F]3F4AP in healthy human volunteers.

Methods

Four healthy volunteers (2 females) underwent a 4-h dynamic PET scan from the cranial vertex to mid-thigh using multiple bed positions after administration of 368 ± 17.9 MBq (9.94 ± 0.48 mCi) of [18F]3F4AP. Volumes of interest for relevant organs were manually drawn guided by the CT, and PET images and time-activity curves (TACs) were extracted. Radiation dosimetry was estimated from the integrated TACs using OLINDA software. Safety assessments included measuring vital signs immediately before and after the scan, monitoring for adverse events, and obtaining a comprehensive metabolic panel and electrocardiogram within 30 days before and after the scan.

Results

[18F]3F4AP distributed throughout the body with the highest levels of activity in the kidneys, urinary bladder, stomach, liver, spleen, and brain and with low accumulation in muscle and fat. The tracer cleared quickly from circulation and from most organs. The clearance of the tracer was noticeably faster than previously reported in nonhuman primates (NHPs). The average effective dose (ED) across all subjects was 12.1 ± 2.2 μSv/MBq, which is lower than the estimated ED from the NHP studies (21.6 ± 0.6 μSv/MBq) as well as the ED of other fluorine-18 radiotracers such as [18F]FDG (~ 20 μSv/MBq). No differences in ED between males and females were observed. No substantial changes in safety assessments or adverse events were recorded.

Conclusion

The biodistribution and radiation dosimetry of [18F]3F4AP in humans are reported for the first time. The average total ED across four subjects was lower than most 18F-labeled PET tracers. The tracer and study procedures were well tolerated, and no adverse events occurred.
Appendix
Available only for authorised users
Literature
4.
go back to reference Rasband MN, Trimmer JS, Schwarz TL, Levinson SR, Ellisman MH, Schachner M, et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci. 1998;18:36–47.CrossRef Rasband MN, Trimmer JS, Schwarz TL, Levinson SR, Ellisman MH, Schachner M, et al. Potassium channel distribution, clustering, and function in remyelinating rat axons. J Neurosci. 1998;18:36–47.CrossRef
5.
go back to reference Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature. 1980;283:570–2.CrossRef Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature. 1980;283:570–2.CrossRef
6.
go back to reference Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol. 1981;313:301–15.CrossRef Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol. 1981;313:301–15.CrossRef
7.
go back to reference Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983;60:353–62.CrossRef Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983;60:353–62.CrossRef
12.
go back to reference Ramos-Torres K, Noel J, Vesper D, Rice P, Brugarolas P, Yokell D. cGMP production of [18F]3F4AP for human PET imaging. Society of Nuclear Medicine Annual Meeting Abstracts. 2021;62:1461. Ramos-Torres K, Noel J, Vesper D, Rice P, Brugarolas P, Yokell D. cGMP production of [18F]3F4AP for human PET imaging. Society of Nuclear Medicine Annual Meeting Abstracts. 2021;62:1461.
14.
go back to reference Collier T, Normandin M, El Fakhri G, Vasdev N. Automation of column-switching HPLC for analysis of radiopharmaceuticals and their metabolites in plasma. Soc Nucl Med Ann Meet Abs. 2013;54:1133. Collier T, Normandin M, El Fakhri G, Vasdev N. Automation of column-switching HPLC for analysis of radiopharmaceuticals and their metabolites in plasma. Soc Nucl Med Ann Meet Abs. 2013;54:1133.
Metadata
Title
Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP
Authors
Pedro Brugarolas
Moses Q. Wilks
Jacqueline Noel
Julia-Ann Kaiser
Danielle R. Vesper
Karla M. Ramos-Torres
Nicolas J. Guehl
Marina T. Macdonald-Soccorso
Yang Sun
Peter A. Rice
Daniel L. Yokell
Ruth Lim
Marc D. Normandin
Georges El Fakhri
Publication date
05-10-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05980-w

Other articles of this Issue 2/2023

European Journal of Nuclear Medicine and Molecular Imaging 2/2023 Go to the issue